{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:20:33Z","timestamp":1792131633525,"version":"4.4.0"},"reference-count":44,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1183\/13993003.01783-2025","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:10:19Z","timestamp":1764263419000},"page":"2501783","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Advances in cystic fibrosis: CFTR modulator triple combinations"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2026010801352028000_67.1.2501783.1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026010801352028000_67.1.2501783.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2026010801352028000_67.1.2501783.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01608-2"},{"key":"2026010801352028000_67.1.2501783.4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026010801352028000_67.1.2501783.5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026010801352028000_67.1.2501783.6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.2025.14913","article-title":"Rewriting the chapter on cystic fibrosis: the 2025 Lasker\u2013DeBakey clinical medical research award","volume":"334","author":"Welsh","year":"2025","journal-title":"JAMA"},{"key":"2026010801352028000_67.1.2501783.7","doi-asserted-by":"crossref","first-page":"e198727","DOI":"10.1172\/JCI198727","article-title":"Welsh, Gonz\u00e1lez, and Negulescu share Lasker Award recognizing transformative treatments for people with cystic fibrosis","volume":"135","author":"Singer","year":"2025","journal-title":"J Clin Invest"},{"key":"2026010801352028000_67.1.2501783.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2026010801352028000_67.1.2501783.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026010801352028000_67.1.2501783.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100665"},{"key":"2026010801352028000_67.1.2501783.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02029-2022"},{"key":"2026010801352028000_67.1.2501783.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02435-2024"},{"key":"2026010801352028000_67.1.2501783.13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010801352028000_67.1.2501783.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC"},{"key":"2026010801352028000_67.1.2501783.15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202110-2249OC"},{"key":"2026010801352028000_67.1.2501783.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202011-4153OC"},{"key":"2026010801352028000_67.1.2501783.17","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor\u2013tezacaftor\u2013ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026010801352028000_67.1.2501783.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202109-2121LE"},{"key":"2026010801352028000_67.1.2501783.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01402-2022"},{"key":"2026010801352028000_67.1.2501783.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01794-2023"},{"key":"2026010801352028000_67.1.2501783.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00004-2024"},{"key":"2026010801352028000_67.1.2501783.22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167957"},{"key":"2026010801352028000_67.1.2501783.23","doi-asserted-by":"crossref","first-page":"e184171","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"key":"2026010801352028000_67.1.2501783.24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.202406-1128RL","article-title":"Elexacaftor\/tezacaftor\/ivacaftor markedly reduces Aspergillus fumigatus in cystic fibrosis","volume":"210","author":"Morgan","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010801352028000_67.1.2501783.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2026010801352028000_67.1.2501783.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02096-2022"},{"key":"2026010801352028000_67.1.2501783.27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2024.08.008","article-title":"Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial","volume":"24","author":"Gifford","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026010801352028000_67.1.2501783.28","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00434-9"},{"key":"2026010801352028000_67.1.2501783.29","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0001-2024"},{"key":"2026010801352028000_67.1.2501783.30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Burgel","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026010801352028000_67.1.2501783.31","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.201708-668ps"},{"key":"2026010801352028000_67.1.2501783.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01146-2024"},{"key":"2026010801352028000_67.1.2501783.33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01959-2023"},{"key":"2026010801352028000_67.1.2501783.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2023"},{"key":"2026010801352028000_67.1.2501783.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01855-2024"},{"key":"2026010801352028000_67.1.2501783.36","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00495-2022"},{"key":"2026010801352028000_67.1.2501783.37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512365"},{"key":"2026010801352028000_67.1.2501783.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022"},{"key":"2026010801352028000_67.1.2501783.39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor\u2013tezacaftor\u2013ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026010801352028000_67.1.2501783.40","doi-asserted-by":"crossref","first-page":"103476","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis harbouring two CFTR class I variants: real-world data from the French compassionate programme","volume":"88","author":"Burgel","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026010801352028000_67.1.2501783.41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026010801352028000_67.1.2501783.42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","article-title":"Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype","volume":"14","author":"McKone","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026010801352028000_67.1.2501783.43","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S2213-2600(25)00190-0","article-title":"Sweat chloride and lung function responses to elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: a an analysis of two real-world observational studies","volume":"13","author":"Burgel","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026010801352028000_67.1.2501783.44","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S2213-2600(25)00206-1","article-title":"Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials","volume":"13","author":"Mayer-Hamblett","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01783-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:35:29Z","timestamp":1767864929000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01783-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/13993003.01783-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01783-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}